How do you approach patients with low ER positive (1 - 9%) breast cancer?
How do you counsel them on risk in the curative setting? Do you approach treatment in the metastatic setting any different than patients with >/= 10% ER positivity?
1 Answer
Mednet Member
Medical Oncology · MOSC Medical College Kolenchery
Answered on
The EBCTCG meta-analysis on adjuvant tamoxifen found benefit with tamoxifen use across all subgroups of ER expression, including the low expressors (1-9%). The absolute benefit of tamoxifen may not be significantly high. In my practice, I do offer anti-estrogen therapy in such a setting, but have a ...
Join for free or sign in to see the full answer